Vol. XXX, n.6, 2009 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Founding Editor
A. Onnis
Montréal (Canada)

Editors-in-Chief
M. Marchetti
Montréal (Canada)
P. Bösze
Budapest (Hungary)

Associate Editor
T. Maggino
Padua (Italy)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
   
European Journal of Gynaecological Oncology - Vol. XXX, n.6, 2009
 
   
CONTENTS  
DISTINGUISHED EXPERT SERIES  
Role of professional societies in the global battle against gynecologic cancers 605
L. Elit - Hamilton, CANADA
Gynecological cancer domains in which professional societies are focused on are discussed.
 
 
ORIGINAL ARTICLES  
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up 609
A. van Dalen, J. Favier, E. Hallensleben, A. Burges, P. Stieber, H.W.A. de Bruijn, D Fink, A. Ferrero, P. McGing, A. Harlozinska, Ch. Kainz, J. Markowska, R. Molina, C. Sturgeon, A. Bowman, R. Einarsson, H. Goike - Gouda, THE NETHERLANDS
Results of a 10-year multicentre clinical follow-up of CA125 and TPS in ovarian cancer patients after three chemotherapy courses.
 
Modulation of microRNA associated with ovarian cancer cells by genistein 616
L.P. Parker, D.D. Taylor, J. Kesterson, D.S. Metzinger, C. Gercel-Taylor - Louisville, KY (USA)
miRNA profiles vary during the progression of ovarian cancer. Genistein results in the differential regulation of selected miRNAs.
 
Sentinel lymph node biopsy in vulvar cancer: a pilot study 622
O. Camara, H. Gonnert, J. Herrmann, A. Egbe, H. Diebolder, M. Gajda, W. Michels, I.B. Runnebaum - Jena, GERMANY
SLN dissection is feasible and safe to perform in vulvar cancer cases and is a promising indication for the implementation of the sentinel technique.
 
Emerging concepts in epithelial ovarian cancer: highlights of the 4th Canadian Conference on Ovarian Cancer Research 625
A.A. Tone, M. Letarte, T.J. Brown - Ontario, CANADA
A summary of key ideas, promising research and clinical findings presented at the 4th Canadian Conference on Ovarian Cancer Research.
 
Breast cancer patients with micrometastases in sentinel lymph nodes: differences considering additional metastatic lymph nodes 631
M.J. Carvalho, M.F. Dias, T.S. Silva, S. Custódio, C.F. de Oliveira - Coimbra, PORTUGAL
Predictive factors for additional lymph node invasion in patients with micrometastases in the sentinel lymph node.
 
Proteomics in mammary cancer research 635
A. Fink-Retter, K. Czerwenka, D. Gschwantler-Kaulich, G. Hudelist, K. Pischinger, M. Manavi, E. Kubista, C.F. Singer - Villach, AUSTRIA
More accurate comprehension of the molecular complexities of human tumors is allowed by comparison of DNA or RNA expression, analysis of protein expression in tissues and proteomics.
 
Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival 640

S. Ozuysal, T. Bilgin, T. Ozgur, N. Celik, T. Evrensel - Bursa, TURKEY
COX-2 levels were shown to be increased in serous ovarian carcinomas, but no correlation was found between COX-2 levels and angiogenesis, nm23 expression, clinicopathological parameters, and survival.

 
Plasma concentration of angiopoietin-1, angiopoietin-2 and Tie-2 in cervical cancer 646
E. Kopczyn ´ska, R. Makarewicz, M. Biedka, A. Kaczmarczyk, H. Kardymowicz, T. Tyrakowski - Bydgoszcz, POLAND
Plasma concentrations of Ang-1, Ang-2, Tie-2 and Ang-1/Ang-2 ratio in cervical cancer were significantly higher than in controls.
 
Do women with glandular abnormalities require colposcopy follow-up? 650
C.A. Errington, D. Mansour - Newcastle upon Tyne (U.K.)
A retrospective review was conducted to identify women with cervical glandular abnormalities and showed that community cytological follow-up is safe
 
Sexual and psychological functioning in women after pelvic surgery for gynaecological cancer 652
L. Aerts, P. Enzlin, J. Verhaeghe, I. Vergote, F. Amant - Leuven, BELGIUM
The prevalence of sexual dysfunction and psychological functioning in women who underwent pelvic surgery for gynaecological cancer were examined.
 
Intraoperative assessment of epithelial and non-epithelial ovarian tumors: a 7-year review 657
K. Pavlakis, I. Messini, T. Vrekoussis, P. Yiannou, T. Panoskaltsis, Z. Voulgaris - Athens, GREECE
Frozen section is a method of relatively low accuracy in borderline epithelial tumors, teratomatous tumors and generally in large masses (> 10 cm).
 
Incidence of multiple primary malignancies in women diagnosed with breast cancer 661
F. Stracci, D. D’Alò, T. Cassetti, M. Scheibel, F. La Rosa - Perugia, ITALY
Occurrence of breast cancer reduces the risk of a second colorectum, stomach, pancreas and breast cancer with different histology, and increases melanoma and contralateral breast risk.
 
Endometrial stromal sarcoma: experience from a district hospital and literature review 664
G. Somoye, H. Lawton, S. Havenga - Cambridgeshire (U.K.)
Diagnosis and management of endometrial stromal sarcoma in a district hospital over a 12-year period 1995-2007.
 
Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation - comparison to CA 125 antigen 668
A. Chudecka-Głaz, B. Górski, D. Zielin ´ska, W. Błogowski, I. Wojciechowska, R. Bedner, I. Rzepka-Górska - Szczecin, POLAND
Serum YKL-40 appears to demonstrate no advantage over CA 125 as a biomarker of ovarian cancer.
 
Endometrial carcinoma clinical management: results of a regional survey 672
G. Carlomagno - Rome, ITALY
After collecting information concerning the clinical management of endometrial cancer in 13 different gynecological units of the Campania region, an overall good quality of treatment was confirmed for women desiring treatment close to their residence.
 
Comparison of paired cervical scrape and tumor tissue samples for detection of human papillomaviruses in patients with cervical cancer 675
N. Janc ˇar, B.J. Kocjan, M. Poljak, E. Vrtac ˇnik Bokal - Ljubljana, SLOVENIA
Cervical scrape samples are equally accurate for HPV genotype determination as tissue samples in patients with cervical cancer.
 
Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer 679
D.T. Arioz, H. Camuzcuoglu, H. Toy, S. Kurt, H. Celik, O. Erel - Sanliurfa, TURKEY
The serum levels of paraoxonase and arylesterase activity are compared in patients with endometrial cancer and healthy controls.
 
 
CASE REPORTS  
Brain metastases from epithelial ovarian cancer - report of cases 683
J. Stanistawiak, J. Lubin, J. Markowska - Poznan, POLAND
Case presentations of patients with brain metastases from epithelial ovarian cancer who were admitted to the Department of Oncology, Poznan University of Medical Sciences, Poland between August 1998 and March 2008.
 
Adenoid cystic carcinoma of the Bartholin’s gland in a young patient: Eight-year follow-up 686
I. Korkontzelos, M. Fragkoulidis, A. Stavroulis, N. Apostolikas, E. Terzakis - Athens, GREECE
An adenoid cystic carcinoma of the Bartholin’s gland in a young patient treated by surgery only is reported.
 
A successful pregnancy and delivery after resectoscopic surgery for early invasive endometrial cancer 689
H. Matsumoto, K. Toyofuku, I. Taniguchi, M. Haraoka, T. Utsunomiya, N. Takai - Oita, JAPAN
Resectscopic surgery to preserve fertility among young women who have early invasive endometrial cancer is feasible.
 
Pure vulvar Langerhans cell histiocytosis: a case report and literature review 691
O. Triantafyllidou, K. Giannakopoulos, V. Pergialiotis, M. Simou, A. Lagkadas, P. Alexandrou - Athens, GREECE
Pure vulvar Langerhans cell histiocytosis without systemic involvement is a rare lesion and local excision seems to be the best treatment for these patients.
 
Sclerosing peritonitis associated with bilateral luteinized thecoma, linked to anticonvulsant therapy 695
H. Levavi, G. Sabah, M. Heifetz, M. Feinmesser - Tel Aviv, ISRAEL
A 22-year-old patient receiving carbamazepine underwent surgery for bilateral ovarian luteinized thecoma with sclerosing peritonitis and was treated with tamoxifen.
 
Incidental diagnosis of atypical polypoid adenomyoma in a young infertile woman 701
K. Dinas, A. Daniilidis, E. Drizis, T. Zaraboukas, J. Tzafettas - Thessaloniki, GREECE
A rare case of atypical polypoid adenoma in a young woman is reported.
 
A giant ovarian mucinous cystic neoplasm weighing 8,500 grams with functional stroma. A case report and literature review 704
A. Kondi-Pafiti, C. Bakalianou, C. Dastamanis, K. Papadias, C. Iavazzo, A. Liapis - Athens, GREECE
A case of a giant ovarian mucinous tumor in a 27-year-old woman with functional stroma is presented.
 
Possible relationship between chronic inflammation and pyloric metaplasia in a patient with lobular endocervical glandular hyperplasia 707
K. Takeuchi, T. Tsujino, R. Yasumizu, S. Kitazawa - Kobe, JAPAN
A rare case of localized lobular endocervical glandular hyperplasia adjacent to a cesarean section scar is described.
 
   
Contents index vol. XXX, 2009 711
   
Authors index vol. XXX, 2009 720